NASDAQ:BIIB - Biogen Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $335.27 +3.24 (+0.98 %) (As of 01/17/2019 11:42 AM ET)Previous Close$332.03Today's Range$330.07 - $335.2752-Week Range$249.17 - $388.67Volume12,028 shsAverage Volume1.28 million shsMarket Capitalization$68.01 billionP/E Ratio15.35Dividend YieldN/ABeta0.99 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Biogen (NASDAQ:BIIB) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.29 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $381.8574, suggesting that the stock has a possible upside of 13.90%. The high price target for BIIB is $470.00 and the low price target for BIIB is $262.15. There are currently 7 hold ratings and 22 buy ratings for the stock, resulting in a consensus rating of "Buy."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: BuyBuyBuyBuyConsensus Rating Score: 2.762.752.712.69Ratings Breakdown: 0 Sell Rating(s)7 Hold Rating(s)22 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)7 Hold Rating(s)21 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)8 Hold Rating(s)20 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)9 Hold Rating(s)20 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $381.8574$382.2750$382.8860$361.3019Price Target Upside: 13.90% upside31.45% upside15.97% upside3.68% upsideBiogen (NASDAQ:BIIB) Consensus Price Target History Biogen (NASDAQ:BIIB) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow12/26/2018BTIG ResearchInitiated CoverageBuyHigh12/19/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$394.00 ➝ $401.00Low12/18/2018OppenheimerLower Price TargetOutperform$380.00 ➝ $372.00High12/12/2018Cantor FitzgeraldReiterated RatingBuy$400.00Low11/26/2018Royal Bank of CanadaLower Price TargetSector Perform$338.00Low10/24/2018Leerink SwannSet Price TargetHold$328.00 ➝ $340.00High10/23/2018Raymond JamesSet Price TargetBuy$400.00Medium10/23/2018MizuhoSet Price TargetBuy$427.00Low10/19/2018Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$373.00 ➝ $341.00High10/8/2018CitigroupLower Price TargetBuy ➝ Buy$483.00 ➝ $470.00Low8/7/2018Stifel NicolausInitiated CoverageBuy$394.00High7/26/2018UBS GroupBoost Price TargetBuy ➝ Buy$354.00 ➝ $395.00Medium7/25/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$295.00 ➝ $320.00High7/25/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$323.00 ➝ $348.00High7/25/2018SunTrust BanksBoost Price TargetBuy$321.00 ➝ $392.00High7/24/2018GuggenheimReiterated RatingBuy$410.00High7/24/2018CowenReiterated RatingBuy$408.00High7/23/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$335.00 ➝ $396.00Low7/11/2018Piper Jaffray CompaniesBoost Price TargetOverweight$365.00Low7/9/2018Jefferies Financial GroupBoost Price TargetPositive ➝ Hold$400.00Medium7/9/2018HC WainwrightReiterated RatingBuyMedium7/6/2018NomuraReiterated RatingBuy$420.00High4/25/2018Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$388.00 ➝ $262.15High4/24/2018Credit Suisse GroupSet Price TargetBuy$384.00High3/2/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$403.00 ➝ $393.00Low2/16/2018ArgusDowngradeBuy ➝ HoldMedium2/15/2018William BlairReiterated RatingBuyLow1/26/2018Deutsche BankReiterated RatingBuy$373.00Low10/18/2017Bank of AmericaBoost Price TargetBuy$358.00 ➝ $365.00N/A3/1/2017InstinetInitiated CoverageBuy ➝ Buy$223.03 ➝ $345.00N/A(Data available from 1/17/2017 forward) This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: What are no-load funds?